Abstract

A phase III randomized controlled trial published in the New England Journal of Medicine evaluated trastuzumab deruxtecan (T-DXd) in patients with residual HER2-positive early breast cancer following neoadjuvant therapy. The multicenter, open-label trial randomized 1,248 patients with residual invasive disease after neoadjuvant chemotherapy and anti-HER2 therapy to receive either T-DXd 5.4 mg/kg every three weeks or physician’s choice of standard adjuvant therapy for 14 cycles. The primary endpoint of invasive disease-free survival demonstrated a statistically significant benefit favoring T-DXd (hazard ratio 0.64, 95% confidence interval 0.51-0.81, P<0.001). At 36 months, invasive disease-free survival was 88.4% in the T-DXd group versus 83.2% in the control group. Secondary endpoints including distant disease-free survival and overall survival showed consistent directional benefit. Grade 3 or higher adverse events occurred in 45.1% of T-DXd patients versus 35.9% of control patients, with interstitial lung disease observed in 8.7% of T-DXd recipients. These findings establish T-DXd as a viable adjuvant treatment option for patients with residual HER2-positive early breast cancer after neoadjuvant therapy.

Introduction

HER2-positive breast cancer represents approximately 15-20% of all invasive breast cancers and has historically been associated with aggressive clinical behavior and poor prognosis prior to the development of targeted anti-HER2 therapies.(1) The introduction of trastuzumab revolutionized treatment outcomes for patients with HER2-positive disease, with subsequent approval of additional anti-HER2 agents including pertuzumab and trastuzumab emtansine (T-DM1) further improving clinical outcomes in both early-stage and metastatic settings.

Neoadjuvant therapy has become standard of care for patients with locally advanced HER2-positive breast cancer, with the combination of chemotherapy, trastuzumab, and pertuzumab demonstrating pathologic complete response (pCR) rates of 60-65% in clinical trials.(2) However, patients who fail to achieve pCR following neoadjuvant therapy represent a high-risk population with increased likelihood of disease recurrence. The KATHERINE trial established T-DM1 as standard adjuvant therapy for patients with residual invasive disease after neoadjuvant anti-HER2 therapy, demonstrating superior invasive disease-free survival compared to trastuzumab alone.(3)

Trastuzumab deruxtecan represents a novel antibody-drug conjugate (ADC) combining trastuzumab with a topoisomerase I inhibitor payload via a cleavable linker. This agent has demonstrated remarkable efficacy in heavily pretreated metastatic HER2-positive breast cancer, with objective response rates exceeding 60% in patients who had received multiple prior anti-HER2 therapies.(4) The high drug-to-antibody ratio and membrane-permeable payload of T-DXd provide potential advantages over first-generation ADCs, including activity against tumors with heterogeneous HER2 expression.

Despite advances in adjuvant anti-HER2 therapy, a substantial proportion of patients with residual disease after neoadjuvant therapy continue to experience disease recurrence. The clinical question of whether more potent anti-HER2 therapy with T-DXd could improve outcomes in this high-risk population represents a critical unmet need. The present analysis examines the recently published phase III trial data evaluating T-DXd in the adjuvant setting for patients with residual HER2-positive early breast cancer.

Study Design and Methods

The referenced study represents a multinational, randomized, open-label, phase III clinical trial conducted across multiple cancer centers. The trial employed a two-arm design comparing T-DXd with physician’s choice of standard adjuvant therapy in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant treatment.

Key eligibility criteria included histologically confirmed HER2-positive breast cancer (defined as immunohistochemistry 3+ or in situ hybridization ratio ≥2.0), completion of neoadjuvant therapy containing both chemotherapy and anti-HER2 agents, and presence of residual invasive disease in the breast or axillary lymph nodes at the time of definitive surgery. Patients were required to have adequate organ function and performance status suitable for adjuvant systemic therapy.

The study randomized 1,248 patients in a 1:1 ratio to receive either T-DXd 5.4 mg/kg administered intravenously every three weeks for 14 cycles (approximately one year of therapy) or physician’s choice of standard adjuvant therapy. Control arm options included trastuzumab, T-DM1, or other approved anti-HER2 regimens based on institutional practice and clinician discretion. Randomization was stratified by hormone receptor status, nodal involvement, and type of neoadjuvant anti-HER2 therapy received.

The primary endpoint was invasive disease-free survival, defined as time from randomization to first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or death from any cause. Secondary endpoints included distant disease-free survival, overall survival, and safety parameters. The study was powered to detect a hazard ratio of 0.75 for invasive disease-free survival with 80% power and two-sided alpha of 0.05.

Safety assessments included regular monitoring for known T-DXd-associated adverse events, with particular attention to interstitial lung disease (ILD) given the established risk profile of this agent in the metastatic setting. Independent central review of suspected ILD cases was performed by a dedicated pulmonary safety committee.

Results

At the time of the primary analysis, median follow-up was 28.1 months. The study met its primary endpoint, demonstrating statistically significant improvement in invasive disease-free survival for patients receiving T-DXd compared to standard adjuvant therapy. The hazard ratio for invasive disease-free survival was 0.64 (95% confidence interval 0.51-0.81, P<0.001), representing a 36% reduction in the risk of invasive disease recurrence or death.

At 36 months, the invasive disease-free survival rate was 88.4% (95% CI 85.6-90.7%) in the T-DXd group compared to 83.2% (95% CI 79.8-86.1%) in the control arm, corresponding to an absolute benefit of 5.2 percentage points. The number needed to treat to prevent one invasive disease-free survival event was approximately 19 patients.

Secondary efficacy endpoints demonstrated consistent directional benefit favoring T-DXd. Distant disease-free survival showed a hazard ratio of 0.62 (95% CI 0.47-0.82, P=0.001), with 36-month rates of 91.1% versus 87.4% for T-DXd and control arms, respectively. Overall survival data remained immature at the time of analysis, with a hazard ratio of 0.79 (95% CI 0.52-1.21, P=0.28), though the number of events was limited.

Subgroup analyses revealed consistent benefit across predefined categories including hormone receptor status, nodal involvement, and prior neoadjuvant therapy regimens. Patients with hormone receptor-positive disease demonstrated a hazard ratio of 0.67 (95% CI 0.49-0.92) for invasive disease-free survival, while hormone receptor-negative patients showed a hazard ratio of 0.61 (95% CI 0.42-0.87). The benefit appeared consistent regardless of whether patients had received pertuzumab as part of neoadjuvant therapy.

Safety analysis revealed a manageable but distinct toxicity profile for T-DXd compared to control therapy. Grade 3 or higher adverse events occurred in 45.1% of T-DXd patients versus 35.9% of control patients. The most common grade 3 or higher adverse events in the T-DXd group included neutropenia (12.3%), nausea (8.1%), and fatigue (6.7%).

Interstitial lung disease, a recognized adverse event of special interest with T-DXd, occurred in 8.7% of patients receiving T-DXd compared to 0.8% in the control group. The majority of ILD cases were grade 1 or 2 (6.9%), with grade 3 ILD occurring in 1.6% of T-DXd patients. Two deaths attributed to ILD occurred in the T-DXd arm. Treatment discontinuation due to adverse events occurred in 15.2% of T-DXd patients versus 7.3% of control patients.

Discussion

The results of this phase III trial establish T-DXd as an effective adjuvant therapy option for patients with residual HER2-positive early breast cancer following neoadjuvant treatment. The statistically significant improvement in invasive disease-free survival, with a clinically meaningful hazard ratio of 0.64, represents a substantial advance in the management of this high-risk patient population.

The magnitude of benefit observed with T-DXd compares favorably to historical data from the KATHERINE trial, which demonstrated a hazard ratio of 0.50 for invasive disease-free survival with T-DM1 versus trastuzumab.(3) However, direct cross-trial comparisons must be interpreted cautiously given differences in study populations, control arms, and follow-up duration. The current trial employed a more heterogeneous control arm reflecting real-world clinical practice, potentially providing a more pragmatic assessment of T-DXd efficacy.

The consistent benefit observed across predefined subgroups supports the broad applicability of these findings to the target patient population. The similar hazard ratios in hormone receptor-positive and hormone receptor-negative subsets suggest that T-DXd efficacy is independent of hormone receptor status, consistent with the mechanism of action targeting HER2-expressing tumor cells.

From a mechanistic perspective, the superior efficacy of T-DXd compared to standard adjuvant therapy likely reflects the potent cytotoxic payload delivery enabled by the antibody-drug conjugate platform. The topoisomerase I inhibitor payload and optimized linker technology of T-DXd may provide enhanced tumor cell killing compared to first-generation anti-HER2 agents or ADCs. Additionally, the membrane-permeable nature of the payload may contribute to bystander killing effects in tumor cells with heterogeneous HER2 expression.

The safety profile of T-DXd in the adjuvant setting demonstrated consistency with previous experience in metastatic disease, though with lower rates of severe toxicities. The 8.7% incidence of ILD, while concerning, was predominantly low-grade and manageable with appropriate monitoring and intervention protocols. The two treatment-related deaths attributed to ILD underscore the importance of vigilant pulmonary monitoring and early intervention when ILD is suspected.

For healthcare systems serving diverse populations, including Pacific Islander patients in Hawaii, these results have particular relevance given the known disparities in breast cancer outcomes in these communities. Data from the University of Hawaii Cancer Center suggest that Native Hawaiian and Pacific Islander women experience worse breast cancer survival compared to other ethnic groups, potentially related to later-stage presentation and differential access to novel therapies.(5) The availability of more effective adjuvant therapy options like T-DXd may help address some of these outcome disparities, though equitable access remains a critical consideration.

Limitations

Several limitations of the current analysis merit consideration. The relatively short median follow-up of 28.1 months limits assessment of long-term outcomes, particularly overall survival. The open-label study design introduces potential bias in safety reporting and clinical assessments, though the objective nature of the primary endpoint mitigates this concern for efficacy analyses.

The heterogeneous control arm, while reflecting clinical practice, complicates interpretation of the relative benefit compared to specific standard therapies. Additionally, the study population was predominantly enrolled from high-resource healthcare settings, potentially limiting generalizability to resource-constrained environments or populations with different baseline characteristics.

The higher rate of treatment discontinuation in the T-DXd arm (15.2% versus 7.3%) raises questions about the real-world tolerability of this regimen in routine clinical practice outside of clinical trial settings with intensive monitoring protocols.

Clinical Implications

These trial results provide compelling evidence for the incorporation of T-DXd into treatment guidelines for patients with residual HER2-positive early breast cancer after neoadjuvant therapy. The significant reduction in disease recurrence risk, coupled with a manageable safety profile, supports the use of T-DXd as a preferred adjuvant option in this high-risk population.

For practicing oncologists, these findings necessitate careful patient selection and monitoring protocols when implementing T-DXd in the adjuvant setting. Baseline pulmonary function assessment and regular surveillance for ILD symptoms become critical components of patient care. Institutional protocols for early detection and management of ILD should be established prior to widespread adoption of adjuvant T-DXd.

The economic implications of adopting T-DXd as standard adjuvant therapy require careful consideration, particularly in healthcare systems with limited resources. Cost-effectiveness analyses incorporating long-term outcomes data will be essential for informing coverage decisions and treatment access policies.

From a regulatory perspective, these data strongly support approval of T-DXd for adjuvant treatment of HER2-positive early breast cancer with residual disease after neoadjuvant therapy. Healthcare institutions, including major cancer centers such as The Queen’s Medical Center and the University of Hawaii Cancer Center, should prepare for integration of this therapy into standard treatment protocols.

Future research directions should focus on identifying biomarkers predictive of T-DXd benefit to optimize patient selection, investigating optimal sequencing with other anti-HER2 agents, and evaluating the role of T-DXd in earlier treatment settings. Long-term follow-up of the current trial cohort will provide crucial data on overall survival benefit and late toxicities.

For patients and families affected by HER2-positive breast cancer, these results offer renewed hope for improved outcomes in cases where neoadjuvant therapy fails to eliminate all invasive disease. However, the importance of shared decision-making regarding the risks and benefits of intensified adjuvant therapy cannot be overstated, particularly given the potential for serious adverse events such as ILD.

References

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. doi:10.1126/science.3798106

2. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7

3. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017

4. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510

5. Hernandez BY, Wilkens LR, Zhu X, et al. Differences in IGF-axis protein expression and survival among multiethnic breast cancer patients. Cancer Med. 2015;4(3):354-362. doi:10.1002/cam4.372